NCT07435376RecruitingPhase 2
Intra-lesional Tumor Boost for Bulky Cervical Cancer
A Prospective Phase 2 Clinical Trial of Intra-lesional Cervical Tumor Boost for Bulky Cervical Cancer
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if adding a radiation boost (intra-lesional boost) works to treat patients with large-sized cervical cancer. It will also learn about the safety of this treatment. The main questions it aims to answer are: * Does the extra radiation boost effectively reduce the tumor size before the internal radiation (brachytherapy) treatment begins? * What medical problems (side effects) do participants have when receiving this treatment? Researchers will give this intra-lesional boost to all participants during their standard radiation therapy to see if it helps shrink the tumor more than usual. Participants will: * Receive radiation therapy to the pelvis with a targeted boost to the tumor for about 5 to 6 weeks * Visit the clinic daily for radiation treatment and regularly for checkups Have an MRI scan during the 4th or 5th week of treatment to measure the tumor size * Receive internal radiation therapy (brachytherapy) after finishing the external radiation * Visit the clinic for follow-up checkups and tests for up to 2 years
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (estimated)
- First submitted
- 20 Feb 2026
- Start date
- 23 Feb 2025
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- Seoul National University Bundang Hospital
- Diseases
- Cervical cancer
- NCT number
- NCT07435376
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 17
- From 23 Feb 2025 to the primary completion date, 30 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Diagnosis of other malignancies within 5 years prior to enrollment (Exceptions: carcinoma in situ of the breast and thyroid cancer).
- Patients who are medically unfit for definitive concurrent chemoradiotherapy.
- Patients who have received prior chemotherapy (neoadjuvant chemotherapy) before radiation therapy.
- Patients with prior history of radiation therapy to the abdomen or pelvis.
Other
- Patients unable to provide informed consent due to mental or physical disabilities.
Who the study is looking for
- Patients with histologically confirmed squamous cell carcinoma of the cervix.
- Patients with bulky primary tumor, defined as a tumor volume ≥ 60 cc OR a maximum diameter ≥ 6 cm.
- Patients aged 19 to 80 years at the time of diagnosis.
- Patients with an ECOG performance status of 0 to 2.
- Patients who have voluntarily agreed to participate in the study.
Age in the registry: 19 years to 80 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seoul National University Bundang Hospital Coordinator of this site? Confirm its status | Seongnam-si | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.